Literature DB >> 14576150

Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines.

Chi-Hui Tang1, Elizabeth A Grimm.   

Abstract

The expression of inducible nitric-oxide synthase in melanoma tumor cells was recently shown to correlate strongly with poor patient survival after combination biochemotherapy (p<0.001). Furthermore, evidence suggests that nitric oxide, a reaction product of nitric oxide synthase, exhibits antiapoptotic activity in melanoma cells. We therefore hypothesized that nitric oxide antagonizes chemotherapy-induced apoptosis. Whether nitric oxide is capable of regulating cell growth and apoptotic responses to cisplatin treatment in melanoma cell lines was evaluated. We demonstrate herein that depletion of endogenously produced nitric oxide can inhibit melanoma proliferation and promote apoptosis. Moreover, our data indicate that the depletion of nitric oxide leads to changes in cell cycle regulation and enhances cisplatin-induced apoptosis in melanoma cells. Strikingly, we observed that the depletion of nitric oxide inhibits cisplatin-induced wild type p53 accumulation and p21(Waf1/Cip1/Sdi1) expression in melanoma cells. When cisplatin-induced p53 binding to the p21(Waf1/Cip1/Sdi1) promoter was examined, it was found that nitric oxide depletion significantly reduced the presence of p53-DNA complexes after cisplatin treatment. Furthermore, dominant negative inhibition of p53 activity enhanced cisplatin-induced apoptosis. Together, these data strongly suggest that endogenously produced nitric oxide is required for cisplatin-induced p53 activation and p21(Waf1/Cip1/Sdi1) expression, which can regulate melanoma sensitivity to cisplatin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576150     DOI: 10.1074/jbc.M310821200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma.

Authors:  Yong Qin; Suhendan Ekmekcioglu; Ping Liu; Lyn M Duncan; Gregory Lizée; Nancy Poindexter; Elizabeth A Grimm
Journal:  Mol Cancer Res       Date:  2011-09-27       Impact factor: 5.852

2.  The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10.

Authors:  Keiji Tanese; Elizabeth A Grimm; Suhendan Ekmekcioglu
Journal:  Int J Cancer       Date:  2011-10-23       Impact factor: 7.396

3.  The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.

Authors:  Harriet M Kluger; Mary M McCarthy; Ayesha B Alvero; Mario Sznol; Stephan Ariyan; Robert L Camp; David L Rimm; Gil Mor
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

4.  Expression and significance of factors related to angiogenesis in choroidal melanoma.

Authors:  Qiang Xu; Gui-Qiu Zhao; Jie Zhao; Hong Lin; Ying-Ying Mou; Qing Wang; Wei-Rong Sun
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

Review 5.  Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target.

Authors:  Elizabeth A Grimm; Andrew G Sikora; Suhendan Ekmekcioglu
Journal:  Clin Cancer Res       Date:  2013-07-18       Impact factor: 12.531

Review 6.  Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance.

Authors:  Elizabeth A Grimm
Journal:  Crit Rev Oncog       Date:  2016

7.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

8.  NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma.

Authors:  Deon G Uffort; Elizabeth A Grimm; Julie A Ellerhorst
Journal:  J Invest Dermatol       Date:  2008-07-31       Impact factor: 8.551

9.  Influence of melanosome dynamics on melanoma drug sensitivity.

Authors:  Kevin G Chen; Richard D Leapman; Guofeng Zhang; Barry Lai; Julio C Valencia; Carol O Cardarelli; Wilfred D Vieira; Vincent J Hearing; Michael M Gottesman
Journal:  J Natl Cancer Inst       Date:  2009-08-24       Impact factor: 13.506

Review 10.  Main roads to melanoma.

Authors:  Giuseppe Palmieri; Mariaelena Capone; Maria Libera Ascierto; Giusy Gentilcore; David F Stroncek; Milena Casula; Maria Cristina Sini; Marco Palla; Nicola Mozzillo; Paolo A Ascierto
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.